Biohaven taps Pfizer for global Nurtec push in deal worth up to $1.24B
Since scoring an FDA approval earlier this year to both treat and prevent migraine, Biohaven’s Nurtec ODT has jumped out ahead of Big Pharma rival AbbVie in garnering...
Continue Reading →
